Ventyx biosciences reports first quarter 2025 financial results and highlights recent corporate progress

Topline data from multiple phase 2 studies expected throughout 2025 • q2 readout from vtx3232 study in patients with early parkinson's disease • h2 readout from vtx2735 study in patients with recurrent pericarditis • h2 readout from vtx3232 study in participants with obesity and cardiometabolic risk factors cash, cash equivalents and marketable securities balance of $228.8m as of march 31, 2025 expected to fund planned operations into at least h2 2026 san diego, may 08, 2025 (globe newswire) -- ventyx biosciences, inc. (nasdaq: vtyx) (“ventyx”, “company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported first quarter financial results and highlighted recent pipeline and business progress. “ventyx has established itself as the leader in discovery and development of nlrp3 inhibitors with two novel compounds, vtx3232 and vtx2735 progressing through phase 2 trials in neurodegenerative, cardiovascular, and metabolic indications - disease states thought to be driven by pathologic activation of the nlrp3 inflammasome,” said raju mohan, phd, president and chief executive officer.
VTYX Ratings Summary
VTYX Quant Ranking